Zealand advances danegaptide into a Phase II clinical proof-of-concept study for protection against reperfusion injury
Zealand Pharma A/S announces that the first patient has been…
20 November 2013 | By Zealand Pharma
Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide...